Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

被引：477

作者：

Law, Mansun ^{[1
]}

Maruyama, Toshiaki ^{[1
]}

Lewis, Jamie ^{[4
]}

Giang, Erick ^{[1
]}

Tarr, Alexander W. ^{[5
]}

Stamataki, Zania ^{[6
]}

Gastaminza, Pablo ^{[3
]}

Chisari, Francis V. ^{[3
]}

Jones, Ian M. ^{[7
]}

Fox, Robert I. ^{[8
]}

Ball, Jonathan K. ^{[5
]}

McKeating, Jane A. ^{[6
]}

Kneteman, Norman M. ^{[4
]}

Burton, Dennis R. ^{[1
,2
]}

机构：

[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA

[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA

[3] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA

[4] Univ Alberta, Dept Surg, Edmonton, AB T6G 2S2, Canada

[5] Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England

[6] Univ Birmingham, Sch Med, Inst Biomed Res, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England

[7] Univ Reading, Sch Biol Sci, Reading RG6 6AH, Berks, England

[8] Scripps Mem Hosp, Rheumatol Clin, La Jolla, CA 92037 USA

来源：

NATURE MEDICINE | 2008年 / 14卷 / 01期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nm1698

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

引用

页码：25 / 27

页数：3

共 15 条

[11] Binding of hepatitis C virus to CD81 [J].

Pileri, P ;

Uematsu, Y ;

Campagnoli, S ;

Galli, G ;

Falugi, F ;

Petracca, R ;

Weiner, AJ ;

Houghton, M ;

Rosa, D ;

Grandi, G ;

Abrignani, S .

SCIENCE, 1998, 282 (5390) :938-941

[12] A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells [J].

Rosa, D ;

Campagnoli, S ;

Moretto, C ;

Guenzi, E ;

Cousens, L ;

Chin, M ;

Dong, C ;

Weiner, AJ ;

Lau, JYN ;

Choo, QL ;

Chien, D ;

Pileri, P ;

Houghton, M ;

Abrignani, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1759-1763

[13] Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 [J].

Tarr, AW ;

Owsianka, AM ;

Timms, JM ;

McClure, CP ;

Brown, RJP ;

Hickling, TP ;

Pietschmann, T ;

Bartenschlager, R ;

Patel, AH ;

Ball, JK .

HEPATOLOGY, 2006, 43 (03) :592-601

[14] Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein [J].

Troesch, Myriam ;

Meunier, Isabelle ;

Lapierre, Pascal ;

Lapointe, Nonnand ;

Alvarez, Fernando ;

Boucher, Marc ;

Soudeyns, Hugo .

VIROLOGY, 2006, 352 (02) :357-367

[15] Production of infectious hepatitis C virus in tissue culture from a cloned viral genome [J].

Wakita, T ;

Pietschmann, T ;

Kato, T ;

Date, T ;

Miyamoto, M ;

Zhao, ZJ ;

Murthy, K ;

Habermann, A ;

Kräusslich, HG ;

Mizokami, M ;

Bartenschlager, R ;

Liang, TJ .

NATURE MEDICINE, 2005, 11 (07) :791-796

← 1 2 →